PREOPANC-2 试验:可切除及交界可切除胰腺癌围手术期治疗期间的血栓栓塞事件
本研究基于 PREOPANC-2 随机对照 III 期试验,评估可切除及交界可切除胰腺导管腺癌(PDAC)患者在接受新辅助及辅助治疗期间静脉血栓栓塞(VTE)的发生率及其与生存的关系。
要点
- 可切除及交界可切除 PDAC 患者新辅助/辅助治疗期间 1 年内 VTE 发生率为 9%。
核心结论
- 在 PREOPANC-2 试验中,可切除及交界可切除 PDAC 患者接受新辅助/辅助治疗后 1 年内 VTE 发生率为 9%,且 VTE 与 OS 降低独立相关。
研究设计与样本
- 研究者发起的多中心随机对照 III 期 PREOPANC-2 试验,纳入可切除及交界可切除 PDAC 患者。
- 患者随机分配至新辅助 FFX 方案后手术(FFX 组)或新辅助吉西他滨为基础的放化疗后手术及辅助吉西他滨(CRT 组)。
- VTE 定义为偶发性及症状性下肢或上肢深静脉血栓、肺栓塞、内脏静脉血栓及导管相关血栓,回顾性评估自随机分组至随机分组后 12 个月。
- 采用 Cox 回归分析 VTE 与 OS 的关联。
主要发现
- 325 例患者中 28 例(9%)诊断为 VTE:9 例(3%)术前,19 例(8%)术后。
- 大多数 VTE 为症状性(54%)。
- CRT 组有 2 例患者死于 PE 相关原因。
临床怎么用
- 对可切除及交界可切除 PDAC 患者在新辅助/辅助治疗期间应关注 VTE 风险,VTE 与 OS 降低独立相关。
- 临床试验中需标准化报告血栓栓塞事件。
- 未来需研究新辅助治疗期间血栓预防的潜在获益。
局限性
- VTE 发生情况为回顾性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is associated with a high risk of venous thromboembolism (VTE), which is burdensome and associated with decreased survival. Although neoadjuvant treatment is increasingly used in patients with PDAC, data on VTE in this setting remain scarce. This study evaluated VTE incidence during (neo)adjuvant therapy for resectable and borderline resectable PDAC and its relation to survival. METHODS: This study included patients from the investigator-initiated, multicenter, randomized controlled phase III PREOPANC-2 trial. Patients were randomly assigned to neoadjuvant 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin followed by surgery (FFX arm) or neoadjuvant gemcitabine-based chemoradiotherapy (CRT), followed by surgery and adjuvant gemcitabine (CRT arm). VTE was defined as both incidental and symptomatic lower- or upper-extremity deep vein thrombosis, pulmonary embolism (PE), splanchnic vein thrombosis, and catheter-related thrombosis. VTE occurrence was retrospectively evaluated from random assignment to 12 months after random assignment. The association with overall survival (OS) was analyzed using Cox regression analysis. RESULTS: VTE was diagnosed in 28 of 325 patients (9%): nine (3%) preoperatively and 19 (8%) postoperatively. Most VTEs were symptomatic (54%). Although a higher proportion of patients developed postoperative VTE in the CRT arm (FFX 3% v CRT 12%, P = .02), the 12-month cumulative incidence did not differ between arms (6% v 11%, P = .06). Two patients died from PE-related causes in the CRT arm. VTE was independently associated with reduced OS (adjusted time-varying hazard ratio, 2.13, P = .002). CONCLUSION: VTE occurred in 9% of patients with (borderline) resectable PDAC undergoing (neo)adjuvant treatment in the year after random assignment and was associated with decreased OS. These results underscore the need for standardized reporting of thromboembolic events in clinical trials and future studies assessing the potential benefits of thromboprophylaxis during neoadjuvant therapy.
引用
- Willems RAL, van Diepen AE, Dekker EN, et al. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. J Clin Oncol. 2026. PMID: 41610374. doi:10.1200/JCO-25-01935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。